41.21
2.37%
-1.00
アフターアワーズ:
41.44
0.23
+0.56%
Celldex Therapeutics Inc. (CLDX) 最新ニュース
Unveiling 4 Analyst Insights On Celldex Therapeutics
Benzinga
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
GlobeNewswire Inc.
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Zacks Investment Research
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Zacks Investment Research
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Zacks Investment Research
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
Zacks Investment Research
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
GlobeNewswire Inc.
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
GlobeNewswire Inc.
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
Benzinga
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
GlobeNewswire Inc.
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know
Zacks Investment Research
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
Zacks Investment Research
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
GlobeNewswire Inc.
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
Zacks Investment Research
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GlobeNewswire Inc.
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
GlobeNewswire Inc.
Can UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q4 Earnings?
Zacks Investment Research
Can UnitedHealth (UNH) Q4 Earnings Navigate Through High Costs?
Zacks Investment Research
Street Calls of the Week: Pepsi may fizzle out
Investing.com
Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics
Benzinga
Top 4 Health Care Stocks That May Crash This Month
Benzinga
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
GlobeNewswire Inc.
What 7 Analyst Ratings Have To Say About Celldex Therapeutics
Benzinga
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
大文字化:
|
ボリューム (24 時間):